1. Home
  2. GME vs PBMWW Comparison

GME vs PBMWW Comparison

Compare GME & PBMWW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GME
  • PBMWW
  • Stock Information
  • Founded
  • GME 1996
  • PBMWW N/A
  • Country
  • GME United States
  • PBMWW Canada
  • Employees
  • GME N/A
  • PBMWW 10
  • Industry
  • GME Electronics Distribution
  • PBMWW
  • Sector
  • GME Consumer Discretionary
  • PBMWW
  • Exchange
  • GME Nasdaq
  • PBMWW Nasdaq
  • Market Cap
  • GME N/A
  • PBMWW N/A
  • IPO Year
  • GME 2002
  • PBMWW N/A
  • Fundamental
  • Price
  • GME $27.00
  • PBMWW $0.02
  • Analyst Decision
  • GME Sell
  • PBMWW
  • Analyst Count
  • GME 1
  • PBMWW 0
  • Target Price
  • GME $10.00
  • PBMWW N/A
  • AVG Volume (30 Days)
  • GME 5.8M
  • PBMWW N/A
  • Earning Date
  • GME 03-25-2025
  • PBMWW N/A
  • Dividend Yield
  • GME N/A
  • PBMWW N/A
  • EPS Growth
  • GME N/A
  • PBMWW N/A
  • EPS
  • GME 0.17
  • PBMWW N/A
  • Revenue
  • GME $4,334,000,000.00
  • PBMWW N/A
  • Revenue This Year
  • GME N/A
  • PBMWW N/A
  • Revenue Next Year
  • GME N/A
  • PBMWW N/A
  • P/E Ratio
  • GME $159.05
  • PBMWW N/A
  • Revenue Growth
  • GME N/A
  • PBMWW N/A
  • 52 Week Low
  • GME $9.95
  • PBMWW N/A
  • 52 Week High
  • GME $64.83
  • PBMWW N/A
  • Technical
  • Relative Strength Index (RSI)
  • GME 48.38
  • PBMWW N/A
  • Support Level
  • GME $25.60
  • PBMWW N/A
  • Resistance Level
  • GME $27.76
  • PBMWW N/A
  • Average True Range (ATR)
  • GME 0.99
  • PBMWW 0.00
  • MACD
  • GME 0.11
  • PBMWW 0.00
  • Stochastic Oscillator
  • GME 55.63
  • PBMWW 0.00

About PBMWW Psyence Biomedical Ltd. Warrant

Psyence Biomedical Ltd is a life science biotechnology company pioneering the use of natural psychedelics in mental health and wellbeing. It develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The company has commenced the clinical trial process to evaluate the safety and efficacy of its product candidates. It cultivates natural psilocybin mushrooms at its federally licensed facility in Southern Africa. This product is produced for export to its partners across the world to be processed into a standardized encapsulated product.

Share on Social Networks: